Bring In-House Prostate MRI Fusion to Your Practice with Navigo + SmartBx
Adopting advanced prostate fusion technology is achievable and affordable with UC-CARE's Navigo 4D MRI Fusion Biopsy System and SmartBx Biopsy Management System. Navigo is designed to support both transperineal and transrectal prostate biopsy workflows.
Powerful + Affordable MRI Fusion Biopsy Technology
With Navigo + SmartBx, practices, ASCs, and hospitals can bring advanced MRI fusion biopsy technology in-house while using their existing ultrasound equipment.
Book a Free Demo
Exclusive Technology
Navigo is the only fusion system with MotionLock™, which compensates for patient movement, and SmartSync™ to automatically adapt to your preferred ultrasound, measure, contour, mark biopsies and more.
Continuous real-time tracking ensures Navigo always knows where the needle is throughout the procedure.
Precision Biopsy
SmartBx precision biopsy preserves specimen delivery from needle to slide, ensuring 100% core orientation, no manual tissue manipulation, and increasing detection rates by 25%.*
Simplified workflows eliminate repeated manual image re-registration, support transperineal and transrectal procedures, and streamline workflows. Plus, by using SmartBx, urology practices can save up to 50% on each MRI prostate fusion biopsy pathology case.
Schedule a call to discover how easily you can adopt Navigo + SmartBx as your in-house fusion biopsy platform.
.webp)
Try Before You Buy with UC-CARE
Unlike other fusion biopsy vendors, UC-CARE helps break down cost barriers to swift adoption with a unique pay-for-procedure model that offers practice flexibility without long-term financial commitment.
​
Reduce costs with the fully automated Navigo fusion navigation system. It works with your existing ultrasound equipment, integrates seamlessly into clinical workflows, and makes MRI fusion adoption easier.
Navigo and SmartBx empower practices to harness advanced prostate biopsy technology with an in-house fusion biopsy platform that can help achieve full ROI in the first year.
